Medipost Receives Marketing Approval in New Zealand for Cartistem Treatment

South Korean biotech firm Medipost has announced it has received marketing approval in New Zealand for its cell therapy product Cartistem, indicated for the treatment of knee osteoarthritis.

The drug company Medipost, which specializes in stem cell drugs, announced on Thursday, February 28, that it is pursuing new markets for its most successful product, which has already gained approval in South Korea and Russia.

Cartistem utilizes mesenchymal stem cells derived from umbilical cord blood and has demonstrated efficacy in clinical trials for improving knee osteoarthritis. The company is currently preparing additional regulatory submissions for various other markets.

Medipost aims to expand the global accessibility of its cell therapy products, and the New Zealand approval marks a significant step. The company has also been involved in developing treatments for conditions such as Alzheimer's disease and lung diseases.